Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Orbital inflammatory disease associated with COVID-19 infection

Taher Eleiwa, MD,a
Samar N. Abdelrahman, MD,b
Reem H. ElSheikh, MD,c
and Abdelrahman M. Elhusseiny, MD,c,d

Conjunctival congestion has been reported as the most common ophthalmic manifestation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, affecting 18.4%-31.6% of patients with coronavirus disease 2019 (COVID-19). Orbital inflammatory disease has been rarely reported in association with COVID-19 infection, with only 2 case reports of adolescent patients having been recently published. We present a unique case of orbital myositis in a 10-year-old boy who tested positive for SARS-CoV-2 infection in the absence of typical systemic COVID-19 manifestations. Although it is uncertain whether SARS-CoV-2 infection triggered the inflammation or was coincidental, the possible association of the events is concerning.

Case Report

A 10-year-old, previously healthy boy presented to ophthalmology clinic at Benha University for a 5-day history of left progressive periorbital dull-ache swelling. Additionally, he had drooping of his upper eyelid, binocular horizontal diplopia on left gaze, painful eye movement, redness of the eye, low-grade fever, occasional nausea, and vomiting. His mother reported contact 3 weeks prior to presentation with asymptomatic individuals who were seropositive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The patient denied symptoms of cough, shortness of breath, or general malaise. He was afebrile at presentation (37.5°C).

On examination, best-corrected visual acuity was 20/20 in the right eye and 20/20 in the left eye. No afferent pupillary defect was observed. Intracocular pressure was 14 mm Hg in each eye. There was a moderate left periorbital edema, erythema, mild left ptosis of 2 mm, and a subtle down-in dystopia (Figure 1A), with moderately limited left eye elevation and abduction (Figure 1B). Mild left-sided proptosis was noted on Hertel exophthalmometry (right eye, 16 mm; left eye, 18 mm) and on Nafziger testing (in which the lid of the proptotic eye is seen first when examining from above tangentially over the forehead). Neither palpable masses nor resistance to retropropulsion were found. Slit-lamp examination revealed mild sectorial chemosis and injection over the left lateral rectus muscle, with no conjunctival discharge. Fundus examination was unremarkable bilaterally, with no evidence of optic nerve head swelling. Head and neck examination did not show any lymphadenopathy.

Orbital magnetic resonance imaging (MRI) revealed significant enlargement of the left lateral rectus muscle, involving its belly and tendinous insertions, as well as the ipsilateral lacrimal gland, with mild stranding of the surrounding intraorbital fat and consequent proptosis (Figure 2).

Laboratory analysis showed an elevated erythrocyte sedimentation rate (56 mm/h), positive C-reactive protein level, and positive nasopharyngeal swab reverse-transcriptase polymerase chain reaction (RT-PCR) tests for SARS-CoV-2. The complete blood cell count results, fasting and postprandial blood glucose levels, thyroid-stimulating hormone level, antinuclear antibody level, antineutrophil cytoplasmic antibody level, rheumatoid factor level, QuantiFERON TB-Gold test, urine analysis, computed tomography chest, MRI, and magnetic resonance venography of the brain were normal (Table 1).

Based on the positive RT-PCR test for SARS-CoV-2, home isolation for 2 weeks was advised, and a 5-day oral therapy with azithromycin (AZT) 200 mg/5 ml suspension (5 ml once daily) was started. AZT was prescribed for potential bacterial superinfection and for reducing SARS-CoV-2 viral load and spread.1 For the presumed orbital myositis with the lack of clinical or radiological evidence of infectious orbital cellulitis, oral prednisone (1 mg/kg/day) for 2 weeks was prescribed. Dramatic improvement was noticed 2 days after initiating the steroid regimen. At the 1-month follow-up examination, clinical features and proptosis had resolved completely. Oral prednisone therapy was tapered by 10 mg weekly. Repeated orbital MRI 14 days after initiation of therapy revealed resolution of the swelling of the left lateral rectus muscle and lacrimal gland.

Discussion

Although the exact etiology of orbital myositis is unknown, a variety of autoimmune, infective, drug-related, and neoplastic conditions have been temporally linked to its pathogenesis. Several autoimmune disorders have been associated with orbital myositis, including granulomatosis

https://doi.org/10.1016/j.jaapos.2021.04.002
with polyangiitis, systemic lupus erythematosus, and rheumatoid arthritis. It has also been reported in cysticercosis, herpes zoster ophthalmicus, Whipple disease, and Lyme disease. Several ophthalmic manifestations have been associated with SARS-CoV-2 infection, including dry eye, conjunctival congestion, acute abducens nerve palsy, optic neuropathy, and multiple cranial nerve palsies.

Three cases of orbital inflammation in the context of SARS-CoV-2 infection have been reported. Turbin and colleagues reported 2 adolescent patients presenting with unilateral orbital cellulitis, sinusitis, and radiographic intracranial abnormalities with relatively mild systemic manifestations. SARS-CoV-2 samples were positive confirming COVID-19 infection. They hypothesized that SARS-CoV-2 infection resulted in congested upper respiratory tract and compromised mucociliary clearance, leading to secondary bacterial infection with subsequent orbital cellulitis with intracranial extension. Diaz and colleagues reported a 22-year-old man patient who presented with unilateral acute dacryoadenitis, which was complicated by partial ophthalmoplegia and orbital inflammation despite oral antibiotic therapy and nonsteroidal anti-inflammatory medications. The patient improved rapidly a few days after oral steroid therapy was initiated. Their patient did not have systemic manifestations of COVID-19 infection, and PCR test was negative; however, he tested positive for IgM/IgG SARS-CoV-2 antibodies.

In both reports and in our patient, systemic COVID-19 symptoms were either absent or mild. In our patient, there was evidence of lateral rectus myositis, enlarged lacrimal gland, and signs of orbital inflammation. It is unclear whether SARS-CoV-2 infection triggered the orbital inflammation or was coincidental. Immunohistological studies would have been required to discriminate between direct viral infiltration and a sterile immunological process. We speculate that viral particles may have entered to ocular tissues from respiratory droplets, blood spread of the virus via the lacrimal gland, or from the nasopharynx. It is also possible that SARS-CoV-2 infection induced an immunological process targeting orbital tissue. Autoimmune myositis has been reported as a manifestation of COVID-19 infection.

**Table 1. Summary of laboratory and imaging findings**

| Test                                               | Result                                      |
|----------------------------------------------------|---------------------------------------------|
| ESR                                                | 56 mm in 1st hour                          |
| CRP                                                | Positive                                   |
| Reverse-transcriptase PCR for SARS-CoV-2 (nasopharyngeal swab) | Positive                                   |
| Complete blood count                               | Normal                                     |
| Blood glucose levels                               |                                            |
| Fasting                                            | 79 mg/dL                                    |
| Postprandial (2 hours)                             | 117 mg/dL                                   |
| Thyroid-stimulating hormone level                  | 2.1 mIU/L                                   |
| Antinuclear antibody level                         | Negative                                   |
| Antineutrophil cytoplasmic antibody                | Negative                                   |
| Rheumatoid factor                                  | Negative                                   |
| Quantifeferon TB-Gold test                         | Negative                                   |
| Urine analysis                                     | Normal                                     |
| Computed tomography (chest)                        | No abnormality detected                    |
| MRI and MR venography of the brain                 | No abnormality detected                    |

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TB, tuberculosis.

**FIG 1.** A, External photography showing left-sided upper lid fullness, proptosis (wider palpebral fissure), and conjunctival hyperemia over the left lateral rectus muscle. B, External photograph showing limited abduction and elevation of the left eye.

**FIG 2.** T2-weighted orbital magnetic resonance imaging showing left-sided proptosis, significant enlargement of left lateral rectus muscle (black arrow) and lacrimal gland (white arrow) with mild stranding of the surrounding intraorbital fat.

**Literature Search**

PubMed CENTRAL, Google Scholar, and Ovid MEDLINE were searched in February 2021 using the following terms: orbital myositis, orbital cellulitis, orbital pseudotumor, corona virus, and COVID-19 infection.
A simple pars plana technique for iris enclavation of Artifact-Ophtec aphakic intraocular lenses
Charles Hurth IV, DO,a Margaret Reynolds, MD,b,c and Lawrence Tychsen, MDb,c,d

The Artisan-Ophtec aphakic iris-enclaved anterior chamber intraocular lens (IOL) has been used to advantage in children and adults who lack capsular support for implantation of a standard posterior chamber IOL. However, even the most skilled anterior segment surgeon may encounter difficulties enclaving the IOL to the iris using the enclavation needle. We describe a simple, secure, rapid alternative method for enclaving the IOL that requires only two eye incisions: one at the corneal limbus and the other through the pars plana.

Children treated by lensectomy for ectopia lentis, traumatic lens subluxation or severe persistent fetal vasculature cataract lack capsular support for sulcus implantation of posterior chamber intraocular lenses (IOL).1,2 The iris-enclaved Ophtec-Artisan aphakic IOL (Ophtec USA, Sunrise FL; Ophtec BV, Groningen, The Netherlands) works well in these cases (O’Brien M, et al. J AAPOS 2019;23:e47-8 [Abstract 168]).3-7 The IOL is inserted into the anterior chamber through a limbal incision and reoriented to a horizontal position with a manipulator. An Ophtec enclavation needle is then employed to sweep a wave of iris about 1 mm wide into the gap in the nasal and temporal IOL haptics. However, in some pediatric aphakic eyes, enclavation using the Ophtec needle is unsuccessful. The iris stroma may have lost flexibility, or the iris may bow posteriorly. Both factors preclude creation of an iris fold to secure the haptic gaps. The pars plana technique circumvents these difficulties.

Surgical Technique
The surgery is performed under general anesthesia using standard pediatric techniques. Fiduciary marks are placed on the corneal limbus using a gentian-violet marker at the 9, 12, and 3 o’clock positions to serve as guides for subsequent centration of the IOL. A small conjunctival incision overlying the pars plana is created 3.0 mm behind the corneoscleral limbus in the superotemporal quadrant (Figure 1), exposing several millimeters of bare sclera. A micro-vitrectomiretrial (MVR) blade (Bausch + Lomb Storz, St Louis, MO) blade is used to make a paracentesis port at the 12 o’clock limbus, followed by infusion of carbachol and viscoelastic. The corneal incision is enlarged to 5.4 mm using a 3.2 mm keratome followed by a 5.2 mm keratome. Employing a lens holder (Ophtec USA), the polymethylmethacrylate IOL is inserted into the anterior chamber and positioned over the pupil. A single “x” 9-0 polyglactin-910 suture is placed to close the center of the incision. A Sinskey lens manipulating hook (Katena Products Inc, Parsippany NJ) is inserted into the anterior chamber to rotate the IOL 90°, reorienting the haptics to align with the 3-9 o’clock marks. A stab incision (MVR blade) is made through the previously exposed sclera overlying the pars plana, 3.0 mm from the limbus. The lens holder is reintroduced through the 12 o’clock incision, grasping the IOL and centering the optic over the pupil (Figure 1). The surgeon’s other hand inserts the Sinskey hook through the pars plana port so that it is visible behind